Trinity Biotech is a medical devices business based in the US. Trinity Biotech shares (TRIB) are listed on the NASDAQ and all prices are listed in US Dollars. Trinity Biotech employs 380 staff and has a trailing 12-month revenue of around $58.7 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.77 |
|---|---|
| 52-week range | $1.49 - $4.59 |
| 50-day moving average | $2.55 |
| 200-day moving average | $2.26 |
| Wall St. target price | $3.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-2.67 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.77 from 2024-09-06
| 1 week (2024-08-30) | -11.06% |
|---|---|
| 1 month (2024-08-07) | -35.87% |
| 3 months (2024-06-07) | -15.71% |
| 6 months (2024-03-07) | -20.63% |
| 1 year (2023-09-07) | 152.86% |
|---|---|
| 2 years (2022-09-07) | 52.59% |
| 3 years (2021-09-07) | 2.61 |
| 5 years (2019-09-06) | 36.15% |
Valuing Trinity Biotech stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Trinity Biotech's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Trinity Biotech's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.3. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Trinity Biotech's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
| Revenue TTM | $58.7 million |
|---|---|
| Gross profit TTM | $38.1 million |
| Return on assets TTM | -9.64% |
| Return on equity TTM | -1913.45% |
| Profit margin | -38.01% |
| Book value | $-3.11 |
| Market Capitalization | $18.8 million |
TTM: trailing 12 months
We're not expecting Trinity Biotech to pay a dividend over the next 12 months.
Trinity Biotech's shares were split on a 1:5 basis on 22 February 2024. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Trinity Biotech shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Trinity Biotech shares which in turn could have impacted Trinity Biotech's share price.
Over the last 12 months, Trinity Biotech's shares have ranged in value from as little as $1.49 up to $4.588. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Trinity Biotech's is 1.221. This would suggest that Trinity Biotech's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. The company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland. .
Use this calculator to quickly see potential outcomes of your options trades.
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.